An exploratory analysis of the landmark SELECT trial, reported by the American College of Cardiology on January 13, 2026, has revealed that the GLP-1 receptor agonist semaglutide (2.4 mg weekly) is significantly associated with reduced hospital admissions and shorter lengths of stay. The study focused on 17,604 patients globally who were overweight or obese and had established cardiovascular disease but importantly, did not have diabetes. Patients treated with semaglutide experienced an 11% reduction in the risk of a first hospitalization for any cause. The total number of hospitalizations was lower in the semaglutide group (18.3 vs 20.4 per 100 patient-years), and patients spent fewer days in the hospital overall (157.2 vs 176.2 days per 100 patient-years) compared to the placebo group. These reductions were not limited to cardiovascular events but extended to a broad range of indications, including cardiac issues, infections, respiratory problems, and even admissions for surgical and medical procedures. This crucial finding, corroborating earlier reports on semaglutide's cardiovascular benefits, suggests a broader positive impact on public health and healthcare resource utilization. The primary SELECT trial, published in the New England Journal of Medicine, initially demonstrated a 20% reduction in major adverse cardiovascular events (MACE) with semaglutide in this same patient population. The consistent benefits across various subgroups, including different BMI, age, and sex categories, further underscore the drug's potential. These insights into GLP-1RAs continue to highlight their expanding therapeutic roles beyond initial indications for diabetes and weight management.